WANG, ZHENYU,王振宇,王振宇,LINHARDT, ROBERT J.,林赫德特 罗伯特J,林赫德特 羅伯特J,DORDICK, JONATHAN S.,多迪克 强纳森S,多迪克 強納森S,BHASKAR, UJJWAL,巴斯卡 悠杰沃,巴斯卡 悠傑沃
申请号：
TW101105882
公开号：
TW201309305A
申请日:
2012.02.22
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
The production of bioengineered heparin that is chemically identical to pharmaceutical heparin remains elusive. It has now been shown that heparosan can be treated in a single step base-catalysed reaction that gives optimal levels of N-deacetylation and depolymerization to obtain a product that may be processed to bioengineered heparin that is substantially identical to pharmaceutical heparin. The inventors have also identified relevant factors and algorithms for adjusting reaction conditions to obtain the desired N-deacetylated N-sulfonated product for further processing into bioengineered heparin from variable heparosan sources.在化學上與醫藥肝素相同之生物工程肝素的生產仍未明瞭。現已顯示,可在單一步驟鹼催化之反應中處理肝素前體,該反應產生最佳程度之N-去乙醯化作用及解聚合作用,而獲得可處理成與醫藥肝素實質上相同之生物工程肝素的產物。本發明者亦已識別用於調整反應條件之相關因子及演算法,以自可變化之肝素前體源獲得用於進一步處理成生物工程肝素之期望N-去乙醯化N-磺化產物。
